Biovet AD

Peshtera, Bulgaria
VISIT WEBSITE
Biovet AD is a prominent European biotechnology and pharmaceutical company specializing in the development, manufacture, and marketing of products for animal health, productivity, and industrial applications. As a key manufacturing arm of the Huvepharma group, the company operates large-scale fermentation facilities and produces a wide range of veterinary medicines, vaccines, nutritional feed additives, and enzymes for global markets. With over 60 years of experience, Biovet maintains a strong focus on R&D, microbiology, and chemical processes. The company operates multiple manufacturing sites in Bulgaria (Peshtera, Razgrad, and Botevgrad) and adheres to high international quality standards, including GMP, FDA, and EMA certifications, enabling it to export products to over 100 countries across six continents.
CLASSIFICATION
Company Type:Biotech
Therapeutic Areas:-
Industry:Biotechnology
Sub-Industry:Animal Health / Veterinary Pharmaceuticals
SIZE & FINANCIALS
Employees:1001-5000
Revenue:$100M-$500M
Founded:1961
Ownership:subsidiary
Status:operating
STOCK
Exchange:Bulgarian Stock Exchange
Ticker:53B
PIPELINE
Stage:Commercial
Lead Drug Stage:Commercial
Modalities:Fermentation, Vaccines, Enzymes, Small molecule
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Parent Company:Huvepharma
Key Partnerships:Huvepharma (Parent company and primary commercial partner)
COMPETITION
Position:Leader
Competitors:Zoetis, Boehringer Ingelheim Animal Health, MSD Animal Health, Elanco
LEADERSHIP
Key Executives:
Kiril Domuschiev - Owner/Chairman (Huvepharma)
LINKS
Website:biovet.com
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Biovet AD and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Biovet AD. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.